Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2006

View Archived Issues

Recent data on HDAC inhibitors in neurological conditions

Preclinical data on actively investigated KSP inhibitor from GSK

Gantacurium pharmacodynamics assessed in phase II trial

Study reveals phenoxodiol effects, mechanism in prostate cancer

Cobra signs CRADA with U.S. Navy for ORT-VAC based malaria vaccine

Rencarex completes phase II study in combination interferon alpha-2a

Phase II study of MF-101 for menopausal symptoms completes enrollment

Enrollment complete in first stage of phase II ALS trial of ALS-08

Auxilium discontinues TestoFilm, reallocates resources to AA-4500

NIH releases strategic plan to guide type 1 diabetes research

SIGA-246 gives 100% protection against human smallpox virus in primate trial

Positive phase III findings for Transacin in postherpetic neuralgia

Genmab updates pipeline progress and future plans

Merck KGaA and Glenmark sign agreement for DPP-IV inhibitor GRC-8200

Bayer and Regeneron to collaborate on VEGF Trap-Eye

Recent patents describe novel agents for anxiety, depression, psychosis, etc.

Recent patents disclose new antiinfective agents

Novel treatment strategies for cancer covered in recent patent literature

Compugen selects three new potential therapeutic candidates

Novel sigma receptor antagonists combat cocaine-induced behavioral toxicity

Preclinical data on Merck's novel CB1 agonist MK-0364 reported at the SfN meeting

Differential modulation of mGluR5 activity yields therapeutic potential in CNS disorders

Seroquel SR filed for approval in Canada, E.U.

Adrovance recommended for approval in E.U.

European CHMP issues positive opinion on Diacomit submission

Tandemact recommended for approval in E.U.

Europe's CHMP recommends Hycamtin for new indication

Positive opinion handed down in Europe for new Glivec indication

Aldara recommended for approval for actinic keratosis in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...